Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:FOLD NASDAQ:ICPT NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.91-2.0%$8.43$6.01▼$11.31$1.69B1.132.13 million shs3.20 million shsFOLDAmicus Therapeutics$7.99-0.4%$6.94$5.51▼$12.65$2.47B0.553.46 million shs2.88 million shsICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/AMNKDMannKind$5.57+2.8%$4.19$3.38▼$7.63$1.66B1.025.45 million shs4.16 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-1.98%-4.35%-7.27%-23.72%+2.33%FOLDAmicus Therapeutics-0.37%0.00%+11.13%+32.50%-29.10%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MNKDMannKind+2.77%+0.54%+49.33%+50.13%-9.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.91-2.0%$8.43$6.01▼$11.31$1.69B1.132.13 million shs3.20 million shsFOLDAmicus Therapeutics$7.99-0.4%$6.94$5.51▼$12.65$2.47B0.553.46 million shs2.88 million shsICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/AMNKDMannKind$5.57+2.8%$4.19$3.38▼$7.63$1.66B1.025.45 million shs4.16 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-1.98%-4.35%-7.27%-23.72%+2.33%FOLDAmicus Therapeutics-0.37%0.00%+11.13%+32.50%-29.10%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MNKDMannKind+2.77%+0.54%+49.33%+50.13%-9.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.70111.13% UpsideFOLDAmicus Therapeutics 2.78Moderate Buy$16.00100.25% UpsideICPTIntercept Pharmaceuticals 0.00N/AN/AN/AMNKDMannKind 3.17Buy$11.17100.48% UpsideCurrent Analyst Ratings BreakdownLatest ICPT, FOLD, BCRX, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/2/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.008/26/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.008/25/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/7/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.008/4/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.007/23/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$10.00 ➝ $8.007/17/2025FOLDAmicus TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight7/16/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$9.007/1/2025BCRXBioCryst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $15.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M3.68N/AN/A($2.30) per share-3.44FOLDAmicus Therapeutics$528.29M4.66N/AN/A$0.65 per share12.29ICPTIntercept Pharmaceuticals$285.71M2.78N/AN/A$1.72 per share11.05MNKDMannKind$285.50M5.99$0.14 per share39.05($0.29) per share-19.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/A1.83-6.41%N/A-1.78%11/3/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.12N/A18.58N/A-6.67%-5.07%-1.23%11/5/2025 (Estimated)ICPTIntercept Pharmaceuticals$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/AMNKDMannKind$27.59M$0.1150.6424.22N/A10.87%-32.60%7.81%11/6/2025 (Estimated)Latest ICPT, FOLD, BCRX, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.252.22FOLDAmicus Therapeutics1.923.212.29ICPTIntercept Pharmaceuticals3.124.222.52MNKDMannKindN/A2.502.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%FOLDAmicus TherapeuticsN/AICPTIntercept Pharmaceuticals83.81%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals5.10%FOLDAmicus Therapeutics2.20%ICPTIntercept Pharmaceuticals6.20%MNKDMannKind2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableFOLDAmicus Therapeutics480308.24 million301.46 millionOptionableICPTIntercept Pharmaceuticals34141.83 million39.19 millionOptionableMNKDMannKind400306.83 million298.54 millionOptionableICPT, FOLD, BCRX, and MNKD HeadlinesRecent News About These CompaniesMillennium Management LLC Acquires 2,375,198 Shares of MannKind Corporation $MNKDSeptember 13 at 3:49 AM | marketbeat.comMannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10 at 8:08 PM | seekingalpha.comMannKind (MNKD): A Fresh Look at Valuation Following New United Therapeutics Deal ExpansionSeptember 10 at 6:56 PM | finance.yahoo.comJacobs Levy Equity Management Inc. Boosts Stock Position in MannKind Corporation $MNKDSeptember 10 at 5:04 AM | marketbeat.comMannKind Corporation $MNKD Shares Sold by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Receives Average Recommendation of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comOppenheimer Forecasts Strong Price Appreciation for MannKind (NASDAQ:MNKD) StockSeptember 8, 2025 | americanbankingnews.comMannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comMannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comMannKind Corporation $MNKD Stake Decreased by Nitorum Capital L.P.September 7, 2025 | marketbeat.comPDT Partners LLC Makes New Investment in MannKind Corporation $MNKDSeptember 7, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Given Consensus Rating of "Buy" by AnalystsSeptember 7, 2025 | americanbankingnews.comMannKind (NASDAQ:MNKD) Shares Up 7.4% Following Analyst UpgradeSeptember 7, 2025 | americanbankingnews.comFY2028 EPS Estimates for MannKind Boosted by HC WainwrightSeptember 6, 2025 | marketbeat.comMannKind Corporation $MNKD Shares Sold by Northern Trust CorpSeptember 6, 2025 | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for MannKind (NASDAQ:MNKD) StockSeptember 5, 2025 | marketbeat.comState of Wyoming Boosts Position in MannKind Corporation $MNKDSeptember 5, 2025 | marketbeat.comMannKind Corporation $MNKD Shares Bought by Trexquant Investment LPSeptember 5, 2025 | marketbeat.comWells Fargo & Company Issues Positive Forecast for MannKind (NASDAQ:MNKD) Stock PriceSeptember 5, 2025 | americanbankingnews.comHC Wainwright Has Positive View of MannKind FY2028 EarningsSeptember 5, 2025 | americanbankingnews.comMannKind (NASDAQ:MNKD) Shares Gap Up After Analyst UpgradeSeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICPT, FOLD, BCRX, and MNKD Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$7.91 -0.16 (-1.98%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.90 0.00 (-0.06%) As of 09/12/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Amicus Therapeutics NASDAQ:FOLD$7.99 -0.03 (-0.37%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.94 -0.06 (-0.69%) As of 09/12/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Intercept Pharmaceuticals NASDAQ:ICPTIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..MannKind NASDAQ:MNKD$5.57 +0.15 (+2.77%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.51 -0.06 (-1.08%) As of 09/12/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
